PMID- 30776865
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20190403
IS  - 1673-0860 (Print)
IS  - 1673-0860 (Linking)
VI  - 54
IP  - 2
DP  - 2019 Feb 7
TI  - [Study on the mechanism of miR-497-induced laryngeal squamous cell carcinoma 
      growth inhibition by targeting CDK6].
PG  - 126-132
LID - 10.3760/cma.j.issn.1673-0860.2019.02.006 [doi]
AB  - Objective: To study the effects of miR-497 and CDK6 on the growth of laryngeal 
      squamous cell carcinoma (LSCC). Methods: The expressions of CDK6 mRNA in fresh 
      LSCC specimens, the adjacent normal mucosa of LSCC, and cell lines of LSCC were 
      detected with quantitative real time polymerase chain reaction, pcDNA3.1(+) CDK6 
      plasmids were respectively transfected into the LSCC cells, and MTT assay and 
      clone formation assay were performed to evaluate the growth of LSCC cells. Flow 
      cytometry was employed for cell cycle analysis. SPSS17.0 software was used to 
      analyze the data. Results: CDK6 was highly expressed in LSCC(t=14.01, P=0.009) 
      and the overall survival rate of the patients with high CDK6 expression was less 
      than that with low CDK6 expression, with a significant difference (HR=3.236, 
      P<0.001). Double luciferase reporter gene analysis showed that fluorescence 
      activity in wild type CDK6 group was significantly different from that in control 
      group (P<0.01), while there was no significant difference in the fluorescence 
      activity between mutant CDK6 group and control group (P>0.05). A(490) values were 
      respectively 0.42+/-0.14 (Mean+/-SD) in siRNA Hep-2 group, 0.51+/-0.13 in siRNA TU-212 
      group; 0.98+/-0.16 in control Hep-2 group and 1.17+/-0.20 in control TU-212 group. 
      Colonies were 55+/-4 in siRNA Hep-2 group, 51+/-3 in siRNA TU-212 group, 108+/-6 in 
      control Hep-2 group and 105+/-7 in control TU-212 group, namely, cell growth and 
      clone formation ability in CDK6 siRNA group were significantly lower than those 
      in the control group. Cells cycle was blocked in G0/G1 phase (G0/G1: 
      65.20%+/-10.12% in siRNA Hep-2 group; 63.42%+/-8.97% in siRNA TU-212 group; 
      45.31%+/-7.55% in control Hep-2 group; and 42.37%+/-7.28% in control TU-212 group), 
      and cells decreased obviously in S phase (S: 25.39%+/-5.51% in siRNA Hep-2 group; 
      27.21%+/-5.43% in siRNA TU-212 group; 42.87%+/-6.85% in control Hep-2 group; and 
      44.76%+/-7.02% in control TU-212 group). Compared with miR-497 group, cell growth 
      and clone formation ability in miR-497/CDK6 group were partly restored (all 
      P<0.05). Conclusions: CDK6 expression in LSCC is upregulated, functioning as an 
      oncogene. High expression of CDK6 is a predictor for poor prognosis. miR-497, 
      functioning as a tumor suppressor gene, inhibits the growth of LSCC by targeting 
      CDK6.
FAU - Niu, J T
AU  - Niu JT
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Second Hospital, Tianjin 
      Medical University, Tianjin 300221, China.
FAU - Liu, S G
AU  - Liu SG
AD  - Tianjin Medical University, Tianjin 300000, China.
FAU - Yan, P
AU  - Yan P
AD  - Department of Thyroid Surgery, Henan Province People's Hospital, Zhengzhou 
      450000, China.
FAU - Li, C
AU  - Li C
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Second Hospital, Tianjin 
      Medical University, Tianjin 300221, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
JT  - Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of 
      otorhinolaryngology head and neck surgery
JID - 101247574
RN  - 0 (MIRN497 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.11.22 (CDK6 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinase 6)
SB  - IM
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell/genetics/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cyclin-Dependent Kinase 6/*metabolism
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/*metabolism/pathology
MH  - MicroRNAs/genetics/*metabolism
MH  - Prognosis
MH  - RNA, Small Interfering/metabolism
MH  - Up-Regulation
OTO - NOTNLM
OT  - Carcinoma, squamous cell
OT  - Cyclin-dependent kinase 6
OT  - Laryngeal neoplasms
EDAT- 2019/02/19 06:00
MHDA- 2019/04/04 06:00
CRDT- 2019/02/19 06:00
PHST- 2019/02/19 06:00 [entrez]
PHST- 2019/02/19 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
AID - 10.3760/cma.j.issn.1673-0860.2019.02.006 [doi]
PST - ppublish
SO  - Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Feb 7;54(2):126-132. doi: 
      10.3760/cma.j.issn.1673-0860.2019.02.006.